Patrick Campbell

The first study to examine joint effects of physical activity and sleep duration on mortality risk using accelerometry, results indicate increase activity could negate the effects of short or long sleep duration on cardiovascular and all-cause mortality.

Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.

An analysis of data from the St. Jude Lifetime Cohort Study provides new insight into the risk of long-term diastolic dysfunction associated with cardiotoxic cancer therapies in adult survivors of childhood cancer.

The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk associated with hypertension in children and adolescents.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

The approval, which is for 4 mg naloxone hydrochloride nasal spray, marks the first OTC, nonprescription approval for a naloxone nasal spray and allows the product to be sold directly to consumers in a variety of retail locations well as online.

A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.

An analysis of more than 9000 adults aged 40 and older without known cardiovascular disease is shedding new light on the risk of myocardial infarction and mortality associated with subclinical coronary atherosclerosis.

A systematic review and meta-analysis of more than 120 randomized trials offers new insight into the effects of weight regain on cardiometabolic risk up to 5 years after the cessation of a behavioral management program.

A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.

On March 24, the US Food and Drug Administration announced a proposed rule changes aimed at promoting use of safe and suitable salt substitutes with the intent of improving nutrition and reducing chronic illness.

A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

A 14-day randomized clinical trial assessing effects of caffeinated coffee consumption in a population of 100 adult patients, CRAVE offers what could be the most definitive insight yet into the effects of coffee consumption on overall health.

The US FDA has approved an indication for evinacumab for use as an adjunct to other lipid-lowering therapies in children with homozygous familial hypercholesterolemia as young as 5 years old, which makes evinacumab the first ANGPTL3 inhibitor indicted for this patient population.

Erin Michos, MD, MHS, discusses her choices for top studies in lipidology from the American College of Cardiology 2023 Scientific Sessions.

An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.

In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1 relatives of people with type 1 diabetes considered to be at risk of progression.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.

A multinational study provides new insight into the impact of suboptimal sleep duration on risk of incident peripheral artery disease.

A 13-week trial examining use of the Control-IQ closed-loop insulin delivery system in children aged 2-6 years, results of PEDAP indicate use of the closed-loop system was associated with a 3 hour per day increase in time in range relative to standard care.

An analysis of data from a 50-year prospective study provides insight into the effects of different pregnancy complications on all-cause mortality later in life.

New research indicates cooccurring edentulism and diabetes mellitus were linked to accelerated cognitive decline among participants in a nationally representative sample of older adults.

An analysis of more than 800,000 children with more than 3.5 million person-years of follow-up indicate those in the upper range of average BMI had a 26% greater risk of developing hypertension, with each per unit increase in BMI associated with a 4% increase in risk of hypertension.

Data from a phase 2 randomized clinical trial demonstrate use of the GLP-1 receptor agonist exenatide could be used as a treatment for idiopathic intracranial hypertension in women.

New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

An analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials provides insight into the atherosclerotic cardiovascular risk associated with high-sensitivity C-reactive protein.

Viet Le, PA-C, offers perspective on a study from Intermountain Healthcare reporting on the epidemiology, relationship to ASCVD risk factors, and clinical outcomes associated with Lp(a) in real-world settings.